Shares of Aduro BioTech Inc. (ADRO) were down 16% on Tuesday as investors were worried about a serious adverse event that was reported in the company’s phase 2a clinical trial of CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer.